STAT+: Drugmakers rely on ‘use codes’ to vastly expand the nature of their patent claims, STAT analysis shows
Amid debate over potential abuse of the U.S. patent system by the pharmaceutical industry, moves…
Category: Pharmaceuticals
STAT+: U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals
A U.S. government agency has threatened Johnson & Johnson with sanctions if the company proceeds…
The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
Pediatricians’ obesity guidelines rest on shaky evidence about eating disorder risks
To address soaring rates of childhood obesity, the American Academy of Pediatrics last year endorsed…
STAT+: BMS immunotherapy boosts responses in lung cancer, setting up Phase 3 study
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint…
STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for…
STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more
And so, another working week will soon draw to a close. Not a moment too…
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in…
STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more
Rise and shine, everyone, another busy day is on the way. However, this is also…
Opinion: STAT+: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma
In a rare display of bipartisan agreement, Congress is getting serious about addressing China’s influence…
STAT+: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams
The U.S. Food and Drug Administration has scolded AbbVie for making false and misleading claims…
Obesity drug worked in children ages 6 to 12, study says, raising hopes and concerns
The first late-stage trial of a GLP-1 drug in young children with obesity showed the…
STAT+: Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries
Amid calls to expand access to medicines in low- and middle-income countries, a new analysis…
With TV drug ads, what you see is not necessarily what you get
Triumphant music plays as cancer patients go camping, do some gardening, and watch fireworks in ads…
STAT+: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its…
STAT+: U.K. charities give $36 million to start new drugs for childhood tumors
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and…
Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after Covid delays
Federal regulators responsible for the safety of the U.S. drug supply are still struggling to…
STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial
A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal,…
STAT+: Greece’s antitrust regulator probes Novartis over practices tied to a pricey eye drug
Greece’s antitrust regulator is investigating allegations that, over a nine-year period, Novartis paid doctors and…
Switching asthma inhalers could reduce carbon emissions, says study
Concerns over health care’s carbon footprint typically revolve around issues like overly-air-conditioned hospitals and single-use…
STAT+: To help migraine patients — and sell more medicines — major drugmakers turn to telehealth
In 2021, Katey Frederking had reached the end of her rope. The 29-year-old was struggling…
STAT+: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals
A U.S. government agency said that a planned move by Johnson & Johnson to alter…
Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides
What does the hiring of a well-known industry dealmaker mean for the future of BioMarin…
STAT+: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi
LONDON — Leqembi, the Alzheimer’s treatment from Eisai and Biogen, has hit another roadblock reaching…
STAT+: Congressional probe questions clinical trials run in China, citing Army involvement
A House committee is investigating whether brand drug companies are collaborating with the Chinese military…
STAT+: Lilly’s Zepbound slashed risk of developing diabetes
Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing…
Opinion: Improving the FDA-EMA parallel scientific advice program to advance complex generics
Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly…
STAT+: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?
As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether…
STAT+: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more
And so, another working week will soon draw to a close. Not a moment too…
Opinion: Gilead must be held accountable for the harm caused by ‘patent hopping’ an HIV treatment
Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June…
STAT+: What do Biden’s drug price comparisons reveal? Not much
WASHINGTON — The White House is touting just how much its new Medicare negotiation process…
Antiviral used for mpox no better than placebo, NIH says
The National Institutes of Health said Thursday that an antiviral often used to treat mpox…
New Medicare drug prices, antimicrobial-resistant meningitis, unlucky American women
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
Medicare drug price negotiation didn’t benefit Biden — but it may help Harris
WASHINGTON — When Vice President Kamala Harris takes the stage at the Democratic National Convention…
STAT+: Medicare announces drug prices for historic first round of negotiations
WASHINGTON — The day drug makers dreaded has finally arrived. Medicare officials on Thursday unveiled…
STAT+: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?
On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building…
FDA approves EpiPen alternative, a nasal spray for anaphylaxis
On Friday, the Food and Drug Administration approved the first needle-free treatment for adults and…
Morning Rounds: Another Ebola outbreak?
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
STAT+: Judge rules against Chamber of Commerce in Medicare drug negotiation lawsuit
WASHINGTON — A federal judge on Thursday tossed out a U.S. Chamber of Commerce lawsuit…
STAT+: A U.K. trade group scolds Novo again — this time for remarks made by its CEO
Once again, Novo Nordisk has been admonished by a U.K. trade group for violating voluntary…
STAT+: FDA scolds Bristol Myers over a misleading website for a cancer treatment
The U.S. Food and Drug Administration has scolded Bristol Myers Squibb for making false and…
Opinion: Give pharmaceutical execs the benefit of doubt — but they need to work for it
The polarized debate over drug pricing has generated cartoonish, sometimes colorful caricatures of the biopharmaceutical…
STAT+: Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report
LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming…
STAT+: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs
Frustrated by the lack of access to expensive weight loss drugs, North Carolina officials are…
Morning Rounds: The ‘very risky business’ of buying weight loss drugs online
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
Weight loss drugs without a prescription? Study warns it’s a “very risky business”
In the face of ongoing shortages of the obesity and diabetes medications known as GLP-1s,…
Morning Rounds: Grindr gets into health care lobbying
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in…
STAT+: NIH loses suit over censoring social media comments made by animal rights advocates
In a boost for animal rights advocates, a U.S. appeals court ruled that a National…
STAT+: Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests
A new study suggests that an older GLP-1 drug may help protect the brains of…